Cover Image
市場調查報告書

糖尿病黃斑部水腫:開發中產品分析

Diabetic Macular Edema - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213121
出版日期 內容資訊 英文 188 Pages
訂單完成後即時交付
價格
Back to Top
糖尿病黃斑部水腫:開發中產品分析 Diabetic Macular Edema - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 188 Pages
簡介

糖尿病黃斑部水腫(DME),是糖尿病患者的視網膜血管受傷害,血液中的水分和脂肪漏出,在視物中心部位的黃斑部產生浮腫的狀態(黃斑部水腫)。有視野不良、飛蚊症、複視的症狀,未治療的話會導致失明。原因是年齡和糖尿病。

本報告提供糖尿病黃斑部水腫治療藥的開發情形調查分析、開發中產品的概要、臨床實驗的各階段的產品概要,再加上主要企業簡介、藥物簡介、開發中產品的最新趨勢、最新消息和新聞稿等相關有系統的資訊。

目錄

簡介

糖尿病黃斑部水腫概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

治療藥的開發作的企業

  • F. Hoffmann-La Roche Ltd.
  • Allergan, Inc.
  • pSivida Corp.
  • GlaxoSmithKline plc
  • Quark Pharmaceuticals, Inc.
  • 參天製藥
  • Astellas Pharma Inc.
  • 興和
  • Pfizer Inc.
  • Genmab A/S
  • TheraKine Ltd.
  • iCo Therapeutics Inc.
  • NicOx S.A.
  • Regeneron Pharmaceuticals, Inc.
  • Handok Inc.
  • ThromboGenics NV
  • Foamix Ltd.
  • Acucela Inc.
  • 千壽製藥
  • Molecular Design International, Inc.
  • Pfenex Inc.
  • Icon Bioscience, Inc.
  • Eleven Biotherapeutics
  • Ampio Pharmaceuticals, Inc.
  • ActiveSite Pharmaceuticals, Inc.
  • AlphaMab Co., Ltd

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • dexamethasone acetate
  • aflibercept
  • fluocinolone acetonide
  • aflibercept
  • DMI-5207
  • betamethasone
  • darapladib
  • iCo-007
  • ocriplasmin
  • ripasudil
  • PF-655
  • MP-0112
  • AKB-9778
  • difluprednate
  • PF-04634817
  • 49-B
  • dexamethasone dipropionate
  • KH-902
  • ALG-1001
  • fluticasone propionate
  • ranibizumab
  • emixustat hydrochloride
  • teprotumumab
  • nesvacumab
  • Drug For Diabetic Macular Edema
  • NCX-434
  • ASP-440
  • NCX-422
  • AVA-101
  • ranibizumab biosimilar
  • Plasma Kallikrein Inhibitors Programme
  • EBI-018
  • Small Molecule to Inhibit VAP-1 for Diabetic Macular Edema
  • EBI-029
  • Plasma Kallikrein Inhibitors Programme
  • OPK-20018
  • ranibizumab biosimilar
  • Protein Therapeutic For Diabetic Macular Edema
  • Peptide For Diabetic Macular Edema
  • HL-5511
  • minocycline Gel

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9005IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 20, 5, 1, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Diabetic Macular Edema - Overview 8
  • Diabetic Macular Edema - Therapeutics Development 9
  • Pipeline Overview 9
  • Pipeline by Companies 10
  • Pipeline by Universities/Institutes 14
  • Products under Development by Companies 15
  • Products under Development by Universities/Institutes 18
  • Diabetic Macular Edema - Therapeutics Assessment 19
  • Assessment by Target 19
  • Assessment by Mechanism of Action 22
  • Assessment by Route of Administration 26
  • Assessment by Molecule Type 28
  • Diabetic Macular Edema - Companies Involved in Therapeutics Development 30
  • Aciont Inc 30
  • ActiveSite Pharmaceuticals Inc 30
  • Acucela Inc 31
  • Aerpio Therapeutics Inc 31
  • Allergan Plc 32
  • Ampio Pharmaceuticals Inc 32
  • Araim Pharmaceuticals Inc 33
  • Boehringer Ingelheim GmbH 33
  • Cell Medica Ltd 34
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd 34
  • Chong Kun Dang Pharmaceutical Corp 35
  • Clearside BioMedical Inc 35
  • Coherus BioSciences Inc 36
  • EyeGate Pharmaceuticals Inc 36
  • F. Hoffmann-La Roche Ltd 37
  • Formycon AG 37
  • Genmab A/S 38
  • GlaxoSmithKline Plc 38
  • Icon Bioscience Inc 39
  • Kala Pharmaceuticals Inc 39
  • Kalvista Pharmaceuticals Ltd 40
  • Kowa Company Ltd 40
  • Lupin Ltd 41
  • Mabion SA 41
  • Oculis ehf 42
  • Ohr Pharmaceutical Inc 42
  • Oxular Ltd 43
  • Pfizer Inc 43
  • pSivida Corp 44
  • Regeneron Pharmaceuticals Inc 44
  • Santen Pharmaceutical Co Ltd 45
  • SciFluor Life Sciences LLC 45
  • Senju Pharmaceutical Co Ltd 46
  • Stealth BioTherapeutics Inc 46
  • ThromboGenics NV 47
  • Verseon Corp 47
  • Xbrane Biopharma AB 48
  • Diabetic Macular Edema - Drug Profiles 49
  • (aflibercept + nesvacumab) - Drug Profile 49
  • abicipar pegol - Drug Profile 51
  • ACU-6151 - Drug Profile 55
  • ACX-107 - Drug Profile 56
  • aflibercept biosimilar - Drug Profile 57
  • aflibercept biosimilar - Drug Profile 58
  • AKB-9778 - Drug Profile 59
  • ALG-1001 - Drug Profile 63
  • Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 67
  • ARP-1536 - Drug Profile 68
  • ASPPDC-010 - Drug Profile 69
  • BI-1026706 - Drug Profile 70
  • Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 72
  • brolucizumab - Drug Profile 73
  • bromfenac sodium - Drug Profile 75
  • cibinetide - Drug Profile 76
  • conbercept - Drug Profile 79
  • danazol - Drug Profile 81
  • darapladib - Drug Profile 85
  • dexamethasone acetate - Drug Profile 88
  • dexamethasone acetate - Drug Profile 93
  • dexamethasone dipropionate XR - Drug Profile 94
  • dexamethasone palmitate - Drug Profile 95
  • difluprednate - Drug Profile 96
  • Drug for Diabetic Macular Edema - Drug Profile 97
  • EBI-031 - Drug Profile 98
  • elamipretide - Drug Profile 99
  • fluocinolone acetonide SR - Drug Profile 107
  • HO-10 - Drug Profile 116
  • JDE-006 - Drug Profile 117
  • KPI-285 - Drug Profile 118
  • KVD-001 - Drug Profile 119
  • LKA-651 - Drug Profile 121
  • loteprednol etabonate - Drug Profile 122
  • NM-108 - Drug Profile 125
  • PF-655 - Drug Profile 126
  • ranibizumab biosimilar - Drug Profile 129
  • ranibizumab biosimilar - Drug Profile 130
  • ranibizumab biosimilar - Drug Profile 131
  • ranibizumab biosimilar - Drug Profile 133
  • ranibizumab biosimilar - Drug Profile 134
  • ranibizumab biosimilar - Drug Profile 135
  • RG-7716 - Drug Profile 136
  • ripasudil - Drug Profile 138
  • SF-0166 - Drug Profile 140
  • Small Molecule for Diabetic Macular Edema - Drug Profile 142
  • Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 143
  • Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile 144
  • squalamine lactate - Drug Profile 145
  • teprotumumab - Drug Profile 153
  • TG-931 - Drug Profile 155
  • THR-149 - Drug Profile 156
  • THR-317 - Drug Profile 157
  • triamcinolone acetonide - Drug Profile 160
  • triamcinolone acetonide - Drug Profile 161
  • VA-999272 - Drug Profile 167
  • Diabetic Macular Edema - Dormant Projects 168
  • Diabetic Macular Edema - Discontinued Products 170
  • Diabetic Macular Edema - Product Development Milestones 171
  • Featured News & Press Releases 171
  • Appendix 183
  • Methodology 183
  • Coverage 183
  • Secondary Research 183
  • Primary Research 183
  • Expert Panel Validation 183
  • Contact Us 183
  • Disclaimer 184

List of Tables

  • Number of Products under Development for Diabetic Macular Edema, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Diabetic Macular Edema - Pipeline by Aciont Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Acucela Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2017
  • Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
  • Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Formycon AG, H1 2017
  • Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2017
  • Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Lupin Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Mabion SA, H1 2017
  • Diabetic Macular Edema - Pipeline by Oculis ehf, H1 2017
  • Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Oxular Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Pfizer Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by pSivida Corp, H1 2017
  • Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H1 2017
  • Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
  • Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H1 2017
  • Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2017
  • Diabetic Macular Edema - Pipeline by Verseon Corp, H1 2017
  • Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2017
  • Diabetic Macular Edema - Dormant Projects, H1 2017
  • Diabetic Macular Edema - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Diabetic Macular Edema - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Diabetic Macular Edema, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top